This was the stock's second consecutive day of losses.

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma: Redwood City, California Wednesday, April 16, 2025, 18:00 Hrs [IS ...

Precision, speed and analytical expertise took center stage as geospatial engineers assigned to the 517th Geospatial Planning Cell ...

Genuine Parts Co. closed 27.83% short of its 52-week high of $164.45, which the company achieved on April 18th.

The objective of this research was to reveal the significance of GPC in the evaluation of commercially accessible plastics that are employed in modern engineering materials. Here, five kinds of ...

The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously ...

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100: Redwood City, California Tuesday, April 15, 2025, 18:00 Hrs [IST] Exicure, Inc., an early-stage bio ...

Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), ...

Investors who anticipate trading during these times are strongly advised to use limit orders. Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades.

Toronto, Ontario--(Newsfile Corp. - March 26, 2025) - Governance Professionals of Canada (GPC) celebrates the 3rd Annual National Governance Professionals Day (GP Day) on Wednesday, March 26 ...